Thermo Fisher Scientific announces R&D partnership with AstraZeneca BioVentureHub
8 Oct 2025
Thermo Fisher Bioanalytical lab
The PPD™ clinical research business of Thermo Fisher Scientific has announced a new research and development (R&D) partnership with the AstraZeneca BioVentureHub in Gothenburg, Sweden.
The partnership aims to leverage the combined expertise of Thermo Fisher and AstraZeneca to drive innovation and strengthen the life science ecosystem. A dedicated team from Thermo Fisher will co-locate with AstraZeneca scientists to work on collaborative R&D projects with a focus initially on chromatography, molecular genomics and proteomics.
The AstraZeneca BioVentureHub is part of a growing innovation ecosystem in Gothenburg that includes the GoCo Health Innovation City, future home of Thermo Fisher's bioanalytical laboratory that is under construction and expected to begin operations in March 2026. This state-of-the-art facility will serve pharmaceutical and biotech customers in Europe and across the globe, providing leading-edge bioanalytical laboratory capabilities to support all phases of pharmaceutical development to help customers deliver life-changing medicines to patients worldwide.
"This is a unique opportunity to co-locate with AstraZeneca scientists, driving collaborative innovation, strengthening the science ecosystem and driving value generation for all collaborators, giving easy access to cutting edge technologies for emerging life sciences and biotech companies as well as academic groups,” said Leon Wyszkowski, president, analytical services, clinical research, Thermo Fisher Scientific.
“This partnership will enable advancements in areas such as drug and analytical development, further bringing to life Thermo Fisher's mission to enable our customers to make the world healthier, cleaner and safer," he added.
“When two global life science leaders join forces in an open innovation environment, truly exceptional conditions for breakthrough discovery and progress are created. Welcoming Thermo Fisher Scientific into BioVentureHub at AstraZeneca’s strategic R&D campus in Gothenburg - adjacent to GoCo Health Innovation City – marks a significant step and unlocks dynamic opportunities for open scientific co-creation between AstraZeneca and Thermo Fisher Scientific," Magnus Björsne, CEO, AstraZeneca BioVentureHub said.